UniProtKB/Swiss-Prot P09429: Variant p.Gly11Arg

High mobility group protein B1
Gene: HMGB1
Feedback?

Variant information Variant position:

11 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Arginine (R) at position 11 (G11R, p.Gly11Arg). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to large size and basic (R) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In gastric-carcinoma cell line. Any additional useful information about the variant.

Sequence information Variant position:

11 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

215 The length of the canonical sequence.
Location on the sequence:

MGKGDPKKPR G KMSSYAFFVQTCREEHKKKH The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

                              MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Mouse                         MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Rat                           MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Pig                           MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Bovine                        MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Horse                         MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Chicken                       MGKGDPKKPRGKMSSYAFFVQTCREEHKKKH

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 215	High mobility group protein B1
DNA binding	9 – 79	HMG box 1
Region	1 – 97	Sufficient for interaction with HAVCR2
Region	3 – 15	LPS binding (delipidated)
Site	10 – 11	Cleavage; by thrombin:thrombomodulin
Modified residue	3 – 3	N6-acetyllysine
Modified residue	7 – 7	N6-acetyllysine
Modified residue	8 – 8	N6-acetyllysine
Modified residue	12 – 12	N6-acetyllysine
Modified residue	23 – 23	Cysteine sulfonic acid (-SO3H); alternate
Modified residue	28 – 28	N6-acetyllysine
Modified residue	29 – 29	N6-acetyllysine
Modified residue	30 – 30	N6-acetyllysine
Cross	28 – 28	Isoglutamyl lysine isopeptide (Lys-Gln) (interchain with Q-?)

Literature citations
Expression of high-mobility group-1 mRNA in human gastrointestinal adenocarcinoma and corresponding non-cancerous mucosa.
Xiang Y.-Y.; Wang D.-Y.; Tanaka M.; Suzuki M.; Kiyokawa E.; Igarashi H.; Niato Y.; Shen Q.; Sugimura H.;
Int. J. Cancer 74:1-6(1997)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANTS ARG-11; GLU-149 AND GLY-190;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.